BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal
cells.
PURPOSE: Phase I trial to study the effectiveness of the BL22 immunotoxin in treating
patients who have non-Hodgkin's lymphoma or chronic lymphocytic leukemia.